- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We're Reading: Boosters, Mixing-Matching Shots Approved; Climate-Related Health Worsening; Ivermectin-Related Poisonings Rise
The FDA approves Moderna and Johnson & Johnson COVID-19 booster shots and will allow mixing-and-matching for boosters; the health-related effects of climate change are growing; there is a rise in poisonings tied to the antiparasitic drug ivermectin.
FDA Approves Moderna and J&J Boosters, Mixing/Matching Shots
As reported by POLITICO, the FDA yesterday authorized Moderna and Johnson & Johnson (J&J) COVID-19 booster shots, as well as allowing people to receive a different brand of booster shot than their primary vaccine series. Similar to the Pfizer booster, the Moderna booster shot will be available for individuals aged 65 and older or those aged 18 to 64 who are at high risk of severe COVID-19 or work in areas that increase risk. Conversely, all J&J vaccine recipients who are at least 2 months out from their initial shot may get a booster, a decision that was noted to be due to the 1-shot series having decreased efficacy compared with the 2-shot vaccines.
Health-Related Impacts of Climate Change on the Rise
According to 2 reports published yesterday as part of the Lancet Countdown project, health issues associated with climate change, including heat deaths, infectious diseases, and hunger, were found to be growing markedly worse in the United States and around the world. As reported by The Associated Press, study findings indicate that 300 million more days of heatwave exposure was reported among US adults over the age of 65 vs the average baseline between 1986 to 2005—marking the second highest year of exposure recorded since 1986. Currently, 65 of the 84 countries examined were said to allow the burning of fossil fuels, a known cause of climate change.
Unproven COVID-19 Treatment Linked With Poisonings
Reported by Bloomberg, poisonings from ivermectin, an antiparasitic drug with unproven efficacy in treating and preventing COVID-19, rose significantly in August 2021, with 21 incidents compared with less than 1 in prior months. Findings published yesterday in The New England Journal of Medicine indicated that of the 21 people with poisonings recorded by the Oregon Poison Center, 6 were hospitalized, with 4 requiring intensive care. Although ivermectin has been shown to lower replication of SARS-CoV-2 in laboratory dishes, its use in randomized, controlled trials produced no benefit against COVID-19, with improper use resulting in potentially serious adverse effects requiring hospitalization.
Insurance Payer Is Associated With Length of Stay After Traumatic Brain Injury
February 21st 2025Among hospitalized patients with traumatic brain injury, Medicaid fee-for-service was associated with longer hospital stays than private insurance and Medicaid managed care organizations.
Read More
NSCLC Advancements Offer Hope, but Disparities Persist
February 20th 2025Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing disparities in these populations.
Read More
Adapting ACA Access Amid Medicaid Transition and Policy Reversals: Molly Dean
February 19th 2025As enrollment shifts to the Affordable Care Act (ACA) marketplace following the unwinding of Medicaid and the Trump administration begins to implement health policy changes, Molly Dean, MSW, Siftwell's policy advisor, shares insight on how to adapt.
Read More
Cardiovascular Magnetic Resonance Highlights Sex-Specific Characteristics in Aortic Stenosis
February 19th 2025This multicenter study sheds more light on sex-based differences in aortic stenosis (AS) and argues the benefits of using cardiovascular magnetic resonance (CMR) to assess sex-based risks in AS.
Read More
